Racemic synthesis of novel 5',5'-difluoro-2'-methyl-apiose nucleoside phosphonic acid analogs was achieved as potent antiviral agents. Phosphonation was performed by direct displacement of triflate intermediate with diethyl (lithiodifluoromethyl) phosphonate to give the corresponding (α,α-difluoroalkyl) phosphonate. Condensation successfully proceeded from a glycosyl donor with persilylated bases to yield the nucleoside phosphonate analogs. Deprotection of diethyl phosphonates provided the target nucleoside analogs. An antiviral evaluation of the synthesized compounds against various viruses such as HIV, HSV-1, HSV-2 and HCMV revealed that the pyrimidine analogs (cytosine, uracil, and thymine) have weak anti-HIV or HCMV activity.
Introduction
The modification of the nucleosides and/or sugar moiety of a natural nucleoside is an obvious choice for developing new antiviral compounds, and apiose-based nucleoside could serve this purpose.
Recently, apiose 5'-nor nucleoside phosphonate [1] , such as, PMDTA (1), has been synthesized and has shown promising anti-HIV properties. The 4'-C-ethynyl substitution of natural nucleoside has a beneficial effect on anti-HIV activity [2] . Herdewijn et al. reported the synthetic procedure of 3'-C-ethynyl analog of PMTA (2) [3] . This absence of a 4'-hydroxymethyl group avoids problems of steric hindrance during phosphorylation reactions with kinases.
Phosphonates and structurally modified phosphonates isosters can mimic phosphates in biological system [4] . The resistance of the phosphorus-carbon phosphonate linkage to hydrolysis by chemical agents or esterases is one of the features responsible for their increasing popularity. Fluoro-substitution at the α-carbon of phosphonates may increase the effectiveness of these phosphate mimetics as a result both geometric and electronic factors [5] . The replacement of phosphonates by fluorophosphonates has provided a number of analogs showing significant biological activity [6] . 9-(5,5-Difluoro-5-phosphonopentyl)guanine (3) has been utilized as a substrate analog inhibitor of purine nucleoside phosphorylase [7] . 2-Chloro-2',5'-dideoxy-5'-difluoromethylphosphinyl adenosine (2CDPA, 4), the nonhydrolyzable analog of 2-chlorodeoxyadenosine monophosphate was prepared for the treatment of refractory chronic leukemia and hairy cell leukemia to overcome the undesired metabolic pathway of 2CDA [8] .
However, biological testing performed on various T cells showed that 2CDPA does not exhibit expected cytotoxic effect. The lack of cytotoxicity is probably caused by an insufficient level of phosphorylation inside T cells. On the basis of the above encouraging results, we undertook the synthesis of isosteric and isopolar 5',5'-difluoromethyl phosphonate derivatives of apiosyl nucleoside to find more effective antiviral agents.
Experimental Section
Uncorrected melting points were determined using a Mel-temp II laboratory device. Nuclear magnetic resonance (NMR) spectra were recorded using a JEOL 300 
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Fourier transform spectrometer (JEOL, Tokyo, Japan); chemical shifts are reported in parts per million (δ) and signals are reported as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), or dd (doublet of doublets). Ultraviolet (UV) spectra were obtained using a Beckman DU-7 spectrophotometer (Beckman, South Pasadena, CA, USA). Mass spectra (MS) were collected in electrospray ionization (ESI) mode. Elemental analyses were performed using a Perkin-Elmer 2400 analyzer (Perkin-Elmer, Norwalk, CT, USA). Thin layer chromatography (TLC) was performed on Uniplates (silica gel) purchased from Analtech Co. (7558, Newark, DE, USA). All reactions were performed in a nitrogen atmosphere unless otherwise specified. Dry dichloromethane, benzene, and pyridine were obtained by distillation from CaH 2 . Dry tetrahydrofuran (THF) was obtained by distillation from Na and benzophenone immediately prior to use.
(rel)-(3S,4S)-Dihydro-4-(hydroxymethyl)-3-methylfuran-2(3H)-one (7)
To a solution of lactone 6 (2.51 g, 19.6 mmol) in 98 mL of EtOAc, 0.98 g of Pd/C (5% w/w) was added under H 2 atmosphere; the mixture was stirred for 10 h. After filtration of the reaction mixture through a celite pad, the filtrate was concentrated and purified using silica gel column chromatography (EtOAc/hexane, 1:4) to yield compound 7 (2.34 g, 92%). 
(rel)-(3S
t-Butyldimethylsilyl chloride (TBDMSCl) (1.60 g, 10.64 mmol) was added slowly at 0 o C to a solution of 7 (1.26 g, 9.68 mmol) and imidazole (659 mg, 17.24 mmol) in CH 2 Cl 2 (30 mL), and stirred for 8 h at rt. The solvent was evaporated under reduced pressure. The residue was diluted with H 2 O (100 mL) and extracted twice with ethyl acetate (EtOAc) (100 mL×2). The combined organic layer was dried over anhydrous MgSO 4 , filtered, and concentrated under reduced pressure. The residue was purified using silica gel column 
A solution of compound 8 (1.68 g, 6.88 mmol) in toluene (60 mL) was treated with 13.76 mL of 1 M DIBAL-H in hexane at -78 o C for 1 h. The reaction was quenched with 4 mL of methanol and warmed to room temperature for 1 h before aqueous NaHCO 3 (6 mL) and EtOAc (60 mL) were added to the mixture. The resulting mixture was filtered and the filtrate was concentrated to dryness. The residue was purified using silica gel column chromatography (EtOAc/hexane, 1:10) to yield compound 9 (1.44 g, 85%). 
To a cooled solution (-78 o C) of glycoside 11 (315 mg, 2.16 mmol) in pyridine (0.873 mL, 10.8 mmol) and CH 2 Cl 2 (25 mL), triflic anhydride (730 mg, 2.59 mmol) was slowly added. After 3.5 h, the reaction mixture was poured into a mixture of ice and sodium hydrogen carbonate. The aqueous layer was extracted with CH 2 Cl 2 (3×50 mL), and the combined CH 2 Cl 2 solution were dried, and rapidly and repeatedly concentrated with toluene to remove any residual pyridine. The residue was extracted with light petroleum (3×50 mL), and the combined extracted were filtered and cooled. After careful evaporation of additional solvent, the crude residue 12 (594 mg, ~99%) was subjected to next reaction without further purification.
(rel)-
To a solution of diisopropylamine (521 µL, 3.72 mmol) and HMPA (647 µL, 3.72 mmol) at -78 and Et 2 O (18.6 mL). The aqueous layer was further extracted with EtOAc (2×74 mL), and the combined organic extracts were dried, filtered, and evaporated. Silica gel flash chromatography (EtOAc/hexane, 1:2) gave 13 (352 mg, 60%) as a form. 
(rel)-Diethyl 2-[(3S,4S,5R/S)-5-acetoxy-
Glycoside 13 (493 mg, 1.56 mmol)was dissolved in EtOAc (13 mL), mixed with a solution of EtOAc (26 mL), acetic anhydride (14.3 mL), acetic acid (10.8 mL) and conc H 2 SO 4 (0.065 mL) at -15 o C, and stirred for 20 h at 0 o C. The reaction was diluted with CHCl 3 (97 mL) and poured into cold 5% aqueous NaHCO 3 (130 mL). The organic layer was separated and the aqueous layer extracted with CHCl 3 (3×35 mL). The combined organic layers were washed with brine, dried and evaporated to dryness. The residue was purified using silica gel column chromatography (EtOAc/hexane, 1:3) to yield compound 14 (381 mg, 71%) as a form. 
(rel)-Diethyl 4-[(1S,2S,3S
6-Chloropurine (280 mg, 1.81 mmol), anhydrous HMDS (15 mL), and a catalytic amount of ammonium sulfate (15 mg) were refluxed for 16 h to a clear solution. The solvent was then distilled under anhydrous conditions. The residue obtained was dissolved in anhydrous 1,2-dichloroethane (12 mL), and to this mixture, a solution of 14 (309 mg, 0.90 mmol) in dry DCE (12 mL) and TMSOTf (0.327 mL, 1.81 mmol) was added, and stirred for 8 h at rt. The reaction mixture was quenched with 12.0 mL of saturated NaHCO 3 , stirred for 2 h, filtered through a Celite pad, and the filtrate obtained was then extracted twice with CH 2 Cl 2 (2×100 mL). Combined organic layers were dried over anhydrous MgSO 4 , filtered, and concentrated under vacuum. The residue was purified using silica gel column chromatography (EtOAc/hexane/MeOH, 3:1:0.02) to yield compounds 15α (134 mg, 34%) and 15β (130 mg, 33%), respectively. Data for 15α: 
(rel)-Diethyl 4-[(1R,2S,3S
A solution of 15β (280 mg, 0.64 mmol) in saturated methanolic ammonia (10 mL) was stirred overnight at 66 o C in a steel bomb and the volatiles were evaporated. The residue was purified using silica gel column chromatography (MeOH/CH 2 Cl 2 , 1:14) to yield 16 (163 mg, 61%) as a white solid: UV (MeOH) λ max 260.5 nm; To a solution of compound 16 (159 mg, 0.38 mmol) and 2,6-lutidine (2.65 mL, 22.8 mmol) in 25 mL of dry CH 3 CN was added bromotrimethylsilane (1.16 g, 7.6 mmol) at room temperature under nitrogen. The reaction mixture was continuously refluxed for 22 h. The reaction mixture was concentrated under high vacuum at room temperature, and the residue was coevaporated with MeOH and 0.5 M TEAB solution. Purification by HPLC using reverse phase C 18 and ion exchange with Dowex-Na + resin offered 17 (64 mg, 44%) as a colourless solid (sodium salt) after lyophilization. Condensation of 14 with 2-fluoro-6-chloropurine under Vorbrüggen condensation conditions similar to those described for 15α and 15β yielded 18α and 18β, respectively. Data for 18α: yield 36%; UV (MeOH) λ max 268.5 nm; Dry ammonia gas was bubbled into a stirred solution of 18β (522 mg, 1.14 mmol) in DME (15.0 mL) overnight at rt. Salts were removed by filtration and the filtrate was concentrated under reduced pressure. The residue obtained was purified using silica gel column chromatography (MeOH/CH 2 Cl 2 , 1:10) to produce 19 (49 mg, 10%) and 20 (216 mg, 42%). Data for 19; UV (MeOH) λ max 261.5 nm; 
(rel)-4-[(1R,2S,3S)-1-(2-Amino-6-oxo-9H-purin-9-yl)-tetrahydrofuran-3-yl]-2-methyl-5,5-difluoroethyl-phosphonic acid sodium salt (21)
To a solution of 20 (308 mg, 0.68 mmol) and 2,6-lutidine (4.75 mL, 40.8 mmol) in dry CH 3 CN (27.2 mL), trimethylsilyl bromide (2.08 g, 13.6 mmol) was added at rt. The mixture was stirred for 30 h and the solvent was removed using evaporation with MeOH three times. The residue was dissolved in MeOH (27.2 mL) and 2-mercaptoethanol (0.19 mL, 2.72 mmol), and then NaOMe (147 mg, 2.72 mmol) was added. The mixture was refluxed for 16 h under N 2 , cooled, neutralized with glacial AcOH, and evaporated to dryness under vacuum. The residue obtained was evaporated with methanol. Purification by HPLC using reverse phase C 18 and ion exchange with Dowex-Na + resin yielded 21 (128 mg, 47%) as a colourless solid (sodium salt) after lyophilization. 
(rel)-Diethyl 4-[(1S,2S,3S)-1-(N
Condensation of 14 with N 4 -benzoyl cytosine under Vorbrüggen condensation conditions similar to those described for 15α and 15β yielded 22α and 22β as solids. Data for 22α: yield 31%; 
(rel)-4-[(1R,2S,3S)-1-(4-Amino-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)-tetrahydrofuran-3-yl]-2-methyl-5,5-difluoroethyl-phosphonic acid sodium salt (24)
Final cytosine analogue 24 was synthesized from 23 by the similar deprotection procedure as described for 17: Yield 51%; UV (H 2 O) λ max 271.5 nm; 
(rel)-Diethyl 4-[(1S,2S,3S
Uracil analogues were synthesized using the similar Vorbrüggen condensation conditions as described for the synthesis of 6-chloropurine analogues 15α and 15β. Data for 25α: yield 33%; 
Thymine analogs were synthesized using the similar Vorbrüggen condensation conditions as described for the synthesis of 6-chloropurine analogues 15α and 15β. Data for 26α: yield 35%; Uracil phosphonic acid analog 27 was synthesized from 25β using the similar hydrolysis conditions as described for 18: Yield 45%; UV (H 2 O) λ max 260.5 nm; 
Results and Discussion
Target compounds were synthesized from lactone derivative 6, which was readily obtained from 1,3-dihydroxyacetone, as previously described (Scheme 1) [9] .
Hydrogenation of 2-methyl-butenolide 6 was achieved with 5% Pd/C under H 2 treatment with a yield of 92% to give lactone 7. Protection [10] of 7 with TBDMSCl in methylene chloride at 25 o C furnished the desired O-silyl ether 8, which was converted to lactol 9 by DIBALH reduction in toluene at -78 o C for 1.0 h in 77% two step yield. Protection of anomeric position was needed prior to phosphonation. Hence, methoxylation of anomeric position furnished glycoside 10 in a 83% yield using the conditions [CH(OMe) 3 , BF 3 /Et 2 O] even in the presence of acid labile silyl protection group [11] . Removal of the TBDMS group of glycoside 10 by TBAF furnished alcohol 11 with a 88% yield which was converted to difluorophosphonate derivative 13 using triflation followed by a triflate displacement according to the procedure of Berkowitz et al. [12] The preparation of a suitable glycosylating agent 14 was attempted by direct acetolysis of 13 under acidic conditions (Ac 2 O, AcOH, H 2 SO 4 , EtOAc, 0 o C) [13] to afford an anomeric mixture of 1-O-acetyl-furanoside 14 in a 71% yield (Scheme 2). The synthesis of adenine nucleoside was performed using a Vorbrüggen condensation [14] of compound 14 with silylated 6-chloropurine and trimethylsilyltriflate (TMSOTf) as a catalyst in dichloroethane (DCE) to yield the protected 6-chloropurine derivatives, 15α and 15β, respectively. A complete nuclear overhauser effect (NOE) study between proximal hydrogens verified their relative stereochemistry (Figure 2 ). NOE experiments of both products showed that glycosylation in α-direction is isomer 15α (NOE: H 1β /H 3α , 0.7%), and glycosylation of β-direction is isomer 15β (NOE: H 1α /H 3α , 1.5%). The chlorine group from purine analog 15β was then converted to an amine with methanolic ammonia at 66 o C to produce the adenosine phosphonate derivative 16 in 61% yield. Hydrolysis of the diethyl phosphonate functional groups of 16 with bromotrimethylsilane treatments in CH 3 CN in the presence of 2,6-lutidine yielded adenosine phosphonic acid derivative 17 (Scheme 3) [15] . Condensation of 2-fluoro-6-chloropurine [16] with glycosyl donor 14 proceeded under conditions similar to those used for synthesis of analogues 15α and 15β to yield 18α (36%) and 18β (36%), respectively. The relative stereochemistries of purine analogs 18α and 18β were also determined by the study of NOE experiments between proximal hydrogens. Mild bubbling ammonia into compound 18β in DME yielded 2-fluoro-6-aminopurine [17] analogue 19 (10%) and 2-amino-6-chloropurine analogue 20 (42%), respectively. The 2-amino-6-chloropurine derivative 20 was treated with TMSBr and 2,6-lutidine to yield phosphonic acid and was then treated with sodium methoxide and 2-mercaptoethanol in methanol to produce guanosine phosphonic acid 21 (Scheme 4) [18] . Condensation of N 4 -benzoyl cytosine with glycosyl donor 14 proceeded under conditions similar to those used for the synthesis of adenine analogs to yield 22α (31%) and 22β (32%), respectively. Ammonolysis of 22β followed by deprotection of diethyl phosphonate furnished the target cytosine phosphonic acid 24 (Scheme 5). Also, uracil and thymine nucleoside ana- logs 27 and 28 were also prepared from 14 via condensation and deprotection procedures (Scheme 6).
Biological Activity Evaluation
The antiviral activity of nucleoside phosphonic acid is mostly attributable to their intracellular conversion to the diphosphate form, which is incorporated into the viral genome, causing chain termination [19] . The antiviral assay against several viruses such as the human immunodeficiency virus 1 (HIV-1), herpes simplex virus-1,2 (HSV-1,2) and human cytomegalovirus (HCMV) was performed. As shown in Table 1 , compound cytosine analog exhibited weak antiviral activity against HIV without any cytotoxicity up to 100 µM. [20] Also, uracil and thymine analogs showed weak anti-HCMV activity in the Davis cell line. It is impossible that the sugar moiety of the purine analogs (adenine and guanine) either inhibited diphosphorylation or binding to viral polymerases.
Conclusion
Based on the potent biological activities of the fluorinated phosphonate nucleosides and apiosyl nucleoside phosphonic acid analogs, we designed and successfully synthesized novel 5',5'-difluoro-2'-methyl apiosyl nuclScheme 5. Synthesis of 5',5'-difluoro-2'-methyl-apiosyl cytosine phosphonic acid analogues.
Scheme 6. Synthesis of 5',5'-difluoro-2'-methyl-apiosyl uracil and thymine phosphonic acid analogues. eoside phosphonic acid analogs from 1,3-dihydroxyacetone. Among them, pyrimidine analogs 24, 27 and 28 showed weak anti-HIV or HCMV activity.
